Compare Novartis AG (NVS) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs 22nd Century Group Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Novartis AG is far larger — about 432013.8× 22nd Century Group Inc's market cap, and Novartis AG pays a 3.31% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and 22nd Century Group Inc for 32 Days on average.
| NVS | XXII | |
|---|---|---|
Market Cap | $268.57B | $621.67K |
Volume | 1,532,573 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $483.00 |
52-Week Low | $121.80 | $0.80 |
Typical Hold Time | 82 Days | 32 Days |
Enterprise Value | $309.89B | -$3.69M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
